Skip to main content
logo
Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
303.06
+2.18 (0.72%)
At close: Nov 9, 2026, 4:00 PM EST
306.56
+3.50 (1.15%)
Pre-market: Nov 10, 2026, 7:34 AM EST

Krystal Biotech Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
470.03389.13290.5250.7--
Revenue Growth
25.96%33.95%473.02%---
Gross Profit
443.12366.08270.4547.61--
Operating Income
227.52161.3103.25-97.12-121.3-69.88
Net Income
225.17204.8389.1610.93-139.98-69.57
Earnings Per Share
7.366.843.000.39-5.49-3.13
EPS Growth
10.50%128.00%669.23%---

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,194955.86749.63594.13383.79502.47
Total Debt
8.599.347.268.098.938.02
Net Cash (Debt)
1,186946.52742.37586.04374.86494.44
Net Cash Growth
38.72%27.50%26.68%56.34%-24.19%84.97%
Net Cash Per Share
38.7631.6024.9621.1214.7022.28

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
323.93200.87123.42-88.8-100.57-47.94
Capital Expenditures
-13.85-11.95-4.24-11.8-52.98-68.34
Free Cash Flow
310.08188.91119.18-100.6-153.55-116.27
Free Cash Flow Growth
87.26%58.51%----

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
94.27%94.08%93.09%93.90%--
Operating Margin
48.41%41.45%35.54%-191.56%--
Pretax Margin
55.06%48.69%32.82%25.44%--
Profit Margin
47.91%52.64%30.69%21.56%--
FCF Margin
65.97%48.55%41.02%-198.43%--

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
41.1734.9050.54320.10--
Forward PE
35.0034.8933.31---
P/FCF Ratio
28.9637.8437.81---
PS Ratio
19.1118.3715.5169.02--